Drugs / GSK3050002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02671188 | Jun 2018 → Aug 2019 | autoimmune disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01984047 | Jan 2014 → Feb 2015 | ulcerative colitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3050002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02671188 ↗ |
| Known as | HGS-1035 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297967 ↗ |
| Known as | KANAB071 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297967 ↗ |
| Action | Inhibit | “binds to and neutralizes the action of human CCL20” NCT02671188 ↗ |
| Modality | Monoclonal antibody | “a humanized IgG1 monoclonal antibody against human CCL20” PMID 32325480 ↗ Apr 2020 |
| Route | Intravenous | “GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion” NCT01984047 ↗ |
| Target | CCL20 | “a humanized IgG1 monoclonal antibody against human CCL20” PMID 32325480 ↗ Apr 2020 |